DEVON LAPPIN: Open Payments
NPI 1194235507 · CAPE MAY COURT HOUSE, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,223 in 39 payments from 11 companies in 2025. Trend: 2023 $2,578 · 2024 $1,641 · 2025 $1,223
Food & beverage: $1,223
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 5 | $332 |
| GENZYME CORPORATION | 7 | $261 |
| Regeneron Healthcare Solutions, Inc. | 6 | $184 |
| GlaxoSmithKline, LLC. | 10 | $152 |
| Neurocrine BioSciences, Inc. | 1 | $103 |
| Genentech USA, Inc. | 3 | $55 |
| United Therapeutics Corporation | 2 | $37 |
| Verona Pharma, Inc. | 2 | $35 |
| Grifols USA, LLC | 1 | $29 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $18 |
Products named: DUPIXENT, BREZTRI, NUCALA, INGREZZA, AIRSUPRA, Xolair, TRELEGY ELLIPTA, Tyvaso.
Industry payments across NJ — which companies pay providers there.
